Template:Second-generation BTKi table: Difference between revisions

From Embryology
(Created page with "{| |+ Novel BTK inhibitors in development for treatment of CLL |- ! BTK inhibitor ! BTK binding mechanism ! Selectivity for BTK ! Relevant non-BTK targets ! Phase of clinical...")
 
mNo edit summary
Line 1: Line 1:
{|
{|
|+ Novel BTK inhibitors in development for treatment of CLL
|+ '''Novel BTK Inhibitors for CCL Treatment'''
|-
|-
! BTK inhibitor
! BTK inhibitor
Line 8: Line 8:
! Phase of clinical development
! Phase of clinical development
|-
|-
Acalabrutinib Zanubrutinib Tirabrutinib Vecabrutinib LOXO-305 ARQ-531
| Acalabrutinib  
BTK Bruton’s tyrosine
| Covalent, irreversible
mitogen-activated protein kinase kinase 1
| High
 
| N/A
 
| II/III
Covalent, irreversible Covalent, irreversible Covalent, irreversible Non-covalent, reversible Non-covalent, reversible Non-covalent, reversible
|-
 
| Zanubrutinib
 
| Covalent, irreversible  
High Moderate High Moderate High Low
| Moderate
 
| N/A
N/A
| II/III
N/A
|-
N/A
| Tirabrutinib
ITK
| Covalent, irreversible
N/A
| High
LYN, MEK1
| N/A
 
| I/II
II/III II/III I/II I/II
|-
I I
| Vecabrutinib
| Non-covalent, reversible
| Moderate
| interleukin-2-inducible (ITK)
| I/II
|-
| LOXO-305
| Non-covalent, reversible
| High  
| N/A
| I
|-
| ARQ-531
| Non-covalent, reversible
| Low 
| Lck/Yes novel tyrosine kinase (LYN), mitogen-activated protein kinase kinase 1 (MEK1)
| I
|-
|-
| colspan=5|Table data {{#pmid:31028669|PMID31028669}}
| colspan=5|Table data {{#pmid:31028669|PMID31028669}}
|}
|}

Revision as of 15:00, 30 April 2019

Novel BTK Inhibitors for CCL Treatment
BTK inhibitor BTK binding mechanism Selectivity for BTK Relevant non-BTK targets Phase of clinical development
Acalabrutinib Covalent, irreversible High N/A II/III
Zanubrutinib Covalent, irreversible Moderate N/A II/III
Tirabrutinib Covalent, irreversible High N/A I/II
Vecabrutinib Non-covalent, reversible Moderate interleukin-2-inducible (ITK) I/II
LOXO-305 Non-covalent, reversible High N/A I
ARQ-531 Non-covalent, reversible Low Lck/Yes novel tyrosine kinase (LYN), mitogen-activated protein kinase kinase 1 (MEK1) I
Table data [1]
  1. ↑ Bond DA & Woyach JA. (2019). Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep , , . PMID: 31028669 DOI.